SCHEMBL5484968

SCHEMBL5484968

COc1cc2c(cc1OC)C1CC(O)CCC1N=C2c1ccc(C(=O)N2CCN(c3ccncc3)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.45
ALDH1A1 P00352 2/20 0.45
PDE4D Q08499 2/20 0.44
PDE4B Q07343 2/20 0.44
PDE4A P27815 1/20 0.44
PDE4C Q08493 1/20 0.44
LMNA P02545 2/20 0.44
F10 P00742 1/20 0.43
CYP3A4 P08684 3/20 0.41
CYP2D6 P10635 3/20 0.41
CYP1A2 P05177 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CYP2C9 P11712 2/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 1/20 0.39
SUV39H2 Q9H5I1 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5481118 0.95 PDE4D (0.42) GAAALDH1A1PDE4DPDE4BPDE4A
SCHEMBL5479675 0.88 PDE4D (0.47) ALDH1A1PDE4DPDE4BPDE4APDE4C
SCHEMBL5476733 0.87 CDK5 (0.51) ALDH1A1PDE4DPDE4BPDE4APDE4C
SCHEMBL5056724 0.85 PDE4B (0.43) GAAALDH1A1PDE4DPDE4BPDE4A
SCHEMBL5480188 0.85 PDE4D (0.47) PDE4DPDE4BPDE4APDE4CTLR9
SCHEMBL5476150 0.83 PDE4D (0.46) ALDH1A1PDE4DPDE4BPDE4APDE4C
SCHEMBL5481825 0.83 PDE4D (0.50) GAAALDH1A1PDE4DPDE4BPDE4A
SCHEMBL5479644 0.83 PDE4D (0.45) ALDH1A1PDE4DPDE4BPDE4APDE4C
SCHEMBL2265798 0.82 PDE4D (0.41) GAAALDH1A1PDE4DPDE4BPDE4A
SCHEMBL5476149 0.82 PDE4D (0.43) ALDH1A1PDE4DPDE4BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US claimed
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US disclosed
EP-1725534-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
WO-2005087745-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors PDE4A, PDE4B, PDE4C GAA 815/4885ALDH1A1 651/4885PDE4D 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.